EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 193-202

  Donato, Nicholas J ^a,b   Perez, Margot ^a   Kang, Hyunseok ^d   Siddik, Zahid H ^a   Ling, Yi He ^a,c   Perez Soler, Roman ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CLONING; CONTROLLED STUDY; DNA ADDUCT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERINE CERVIX CARCINOMA;

APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA ADDUCTS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0033985682     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cantley, L. C., Auger, K. R., Carpentar, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. Oncogenes and signal transduction. Cell, 64: 281-301, 1991.
2. Aaronson, S. A. Growth factors and cancer. Science (Washington DC), 254: 1146-1153, 1991.
3. Christen, R. D., Isonishi, S., Jones, J. A., Jekunen, A. P., Horn, D. K., Kroning, R., Gately, D. P., Thiebaut, F. B., Los, G., and Howell, S. B. Signaling and drug resistance. Cancer Metastasis Rev., 13: 175-189, 1994.
4. El-Deiry, W. S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol., 9: 79-87, 1997.
5. Gullick, W. J. Prevalence of aberrant expression of epidermal growth factor receptor in human cancers. Br. Med. Bull., 47: 87-98, 1991.
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A, and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
7. Takishima, K., Griswold-Prenner, I., Ingebritsen, T., and Rosner, M. R. Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP"' kinase. Proc. Natl. Acad. Sci. USA, 88: 2520-2524, 1991.
8. Walker, D. H., and Pike, L. J. Phosphatidylinositol kinase is activated in membranes derived from cells treated with epidermal growth factor. Proc. Natl. Acad. Sci. USA, 84: 7513-7517, 1987.
9. Pawson, T., and Schlessinger, J. Signal transduction by receptor tyrosine kinases. Curr. Biol., 3: 434-442, 1993.
10. Nishikawa, K., Rosenblum, M. G., Newman, R. A., Pandita, T. K., Hittelman, W. N., and Donato, N. J. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. Cancer Res., 52: 4758-4765, 1992.
11. Dixit, M., Yang, J-L., Poirier, M. C., Price, J. O., Andrews, P. A., and Arteaga, C. L. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst., 89: 365-373, 1997.
12. erbB-2 protein and alterations in growth properties in responses to therapy in an ovarian tumor cell line. Cell Growth Differ., 5: 1367-1372, 1994.
13. Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst., 89: 341-343, 1997.
14. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 80: 1605-1611, 1988.
15. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
16. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J. Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cells. Cancer Res., 51: 4575-4580, 1991.
17. c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
18. Pietras, R. J. Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
19. Lowe, S. W. Cancer therapy and p53. Curr. Opin. Oncol., 7: 547-553, 1995.
20. Wosikowski, K., Regis, J. T., Robey, R. W., Alvarez, M., Buter, J. T., Gudas, J. M., and Bates, S. E. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ., 6: 1395-1403, 1995.
21. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifiline. Cancer Res., 55: 1649-1654, 1995.
22. Smith, M. L., and Fornace, A. J. The two faces of tumor suppressor p53. Am. J. Pathol., 148: 1019-1022, 1996.
23. Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Oncogene, 14: 1875-1882, 1997.
24. Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A., McClain, C. D., Claxton, D., and Diesseroth, A. B., High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res., 1: 1051-1057, 1995.
25. WAF1/Cip1 in human brain tumors. Oncogene, 11: 2021-2028, 1995.
26. McDonald, E. R., Wu, G. S., Waldman, T., and El-Deiry, W. S. Repair defect in p21WAF1/CIP1 -/- human cancer cells. Cancer Res., 56: 2250-2255, 1996.
27. Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
28. Ling, Y-H., Priebe, W., and Perez-Soler, R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug resistant cells. Cancer Res., 53: 1845-1852, 1993.
29. Donato, N. J., and Perez, M. Tumor necrosis factor increases p53 expression and p21WAF1 proteolysis in ME-180 cells. J. Biol. Chem., 273: 5067-5072, 1998.
30. Donato, N. J., Yaun, D. H., Hung, M. C., and Rosenblum, M. G. Expression and function of epidermal growth factor receptor control cytotoxicity of tumor necrosis factor in ME-180 cervical carcinoma cells. Cell Growth Differ., 4: 411-419, 1993.
31. Yoshida, M., Khokhar, A. R., and Siddik, Z. H. Biochemical pharmacology of homologous alicyclic mixed amine platinum (II) complexes in sensitive and resistant tumor cell lines. Cancer Res., 54: 3468-3473, 1994.
32. Li, C-CH., O'Connell, C. D., Beckwith, M., and Longo, D. L. Detection of p53 mutations in B cell non-Hodgkin's lymphoma cell lines. Leukemia, 9: 650-655, 1995.
33. Dickstein, B. M., Wosikowski, K., and Bates, S. E. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell. Endocrinol., 110: 205-211, 1997.
34. Waga, S., and Stillman, B. Cyclin-dependent kinase inhibitor p21 modulates the DNA primer-template recognition complex. Mol. Cell. Biol., 18: 4177-4187, 1998.
35. Cayrol, C., Knibiehler, M., and Ducommun, B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene, 16: 311-320, 1998.
36. Fan, Z., Lu, Y., Wu, X., DeBlasio, A., Koff, A., and Mendelsohn, J. Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complexes by epidermal growth factor receptor activation mediates ligand induced A431 cell growth inhibition. J. Cell Biol., 131: 235-242, 1995.
37. Chernov, M. V., Ramana, C. V., Adler, V. V., and Stark, G. R. Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc. Natl. Acad. Sci. USA, 95: 2284-2289, 1998.
38. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdmd-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
39. Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y., and Fu, X. Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (Washington DC), 272: 719-722, 1996.
40. Tchou, W. W., Rom, W. N., and Tchou-Wong, K. M. Novel form of p21(WAF1/CIP1/SDI1) protein in phorbol ester-induced G2/M arrest. J. Biol. Chem., 271: 29556-29560, 1996.
41. Fuchs, S. Y., Adler, V., Pincus, M. R., and Ronai, Z. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA, 95: 10541-10546, 1998.
42. Prabhu, S., Ignatova, A., Park, S. T., and Sun, X. H. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol. Cell. Biol., 17: 5888-5896, 1997.
43. Hiyama, H., Iavarone, A., and Reeves, S. A. Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene, 16: 1513-1523, 1998.
44. Cip/Waf1 by caspases is an early event during DNA-damage induced apoptosis. J. Biol. Chem., 273: 19207-19212, 1998.
45. Maki, C. G., and Howley, P. M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol., 17: 355-363, 1997.
46. Sewing, A., Wiseman, B., Lloyd, A., and Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol., 17: 5588-5597, 1997.
47. Olson, M. F., Paterson, H. F., and Marshall, C. J. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf/Cip1. Nature (Lond.), 394: 295-299, 1998.